



150 W 4th Ave
Vancouver, BC V5Y 1G6
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

2026-01-22

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Tiffany Chiu; **media@abcellera.com**, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; **partnering@abcellera.com**, +1(604)559-9005

Investor Relations: Peter Ahn; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.